ClinicalTrials.gg
RecruitingNCT06783309Updated Nov 12, 2026

CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

A Phase 1/2 interventional study of CNP-103 and Placebo in Type 1 Diabetes Mellitus, T1D and T1DM, sponsored by COUR Pharmaceutical Development Company, Inc.. Recruiting at 45 sites in United States. Open to participants aged 12 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by COUR Pharmaceutical Development Company, Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Nov 12, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
12 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 190 open to participants now, 257 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.

Planned enrollment
428th of 1,242
72 · median 40
Started
2025
with 64 others
Phase 1/2
59 of 1,458
8 open now
Primary completion
2027-08
later than 155 of 256 live
Registered
1,346th of 1,458
by date

Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 428th largest by planned enrollment of the 1,242 interventional ones that give a count, is one of 65 that started in 2025, is one of 59 in phase 1/2, reaches primary completion later than 155 of the 256 other live ones, and was the 1,346th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

190 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:

185 more — sign in →

All 190 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 12 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, or all of them as a file.
02

Study summary

This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-103. The approximately 393-days study consists of a Screening Period (28 days), Treatment Period (90 days), and Post-Dose Evaluations (275 days).

03

Conditions studied

  • Type 1 Diabetes Mellitus
  • T1D
  • T1DM
  • T1DM - Type 1 Diabetes Mellitus
  • Type 1 Diabetes in Adolescence
  • Type 1 Diabetes in Children
  • Type 1 Diabetes (Juvenile Onset)
  • Type 1 Diabetes
  • Type 1 Diabetes Patients
  • Type 1 Diabetes Mellitis

Keywords

  • Diabetes
  • T1D
  • Stage 3
  • Adolescents
  • Adults
  • T1DM
  • Newly Diagnosed
  • Recently Diagnosed
04

Who can participate

Ages eligible
12 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants who are willing and able to provide Institutional Review Board (IRB) approved written and privacy language as per national regulations.
  2. Men and non-pregnant, non-breast-feeding women ages 12-35 years inclusive.
  3. Documented diagnosis of Stage 3 T1D within 180 days prior to study enrollment according to American Diabetes Association (ADA) criteria.
  4. Participants must be on standard of care diabetes management including insulin therapy as a routine and also consisting of a nutrition plan, regular exercise, or other relevant specialty care as required on a patient-by-patient basis.
  5. Participants with a peak stimulated C-peptide of >0.2 nmol/L measured from a screening mixed meal tolerance test (MMTT).
  6. Participants with an episode of diabetic ketoacidosis (DKA) must have a MMTT performed no sooner than 2 weeks after resolution of the DKA event to have a qualifying C-peptide reading.
  7. Participants on systemic or any medication used to treat the symptoms of T1D (other than insulin) must undergo a of at least two weeks prior to enrollment and must agree to use a non-steroid alternative throughout the trial, if necessary, for any disorder requiring corticosteroids. In addition, participants must be on a stable dose of any other medications, other than insulin, for a minimum of 1 month prior to enrollment and must agree not to increase their dose from the Screening Visit through the End of Study Visit unless reviewed and approved by the medical monitor and the principal investigator.
  8. Female participants of non- (e.g., surgical sterilization, no menses for a year).
  9. Women of childbearing potential (WOCBP) who have agreed not to become pregnant during the study, have a negative pregnancy test at Screening Visit, and agree to use 1 highly effective form of starting at initial screening and continuing throughout the entire study to Day 365.
  10. Female participants who agree to not breastfeed starting at initial Screening and throughout the entire study to Day 365.
  11. Female participants who agree to not donate ova, including autologous, starting at initial Screening and throughout the entire study to Day 365.
  12. Male participant and with a spouse or partner of childbearing potential, who themselves and their spouse or partner agree to practice an effective form of birth control as discussed with the study doctor or study staff starting at Screening and throughout the entire study to Day 365.
  13. Participants must weigh >35 kg at Screening for Cohort 1 (100 mg) and Cohort 2 (300 mg); participants must weigh >50 kg at Screening for Cohort 3 (600 mg).
  14. (BMI):

    1. Participants 12-17 years: BMI Z-Score within 5th and 95th percentile based on participant's age (e.g., Baylor College of Medicine Age-based Pediatric Growth Reference Charts: BMI Z-Score and Percentile Calculator)
    2. Participants 18-35 years: 18.0-30.0 (not inclusive)

Exclusion criteria

Exclusion Criteria:

  1. Participants unable to comply with prohibited medication outlined in the protocol.
  2. Exclusion of additional immunomodulation will be at the discretion of the Medical Monitor and study site Investigator.
  3. Participants with a history of tuberculosis or positive Quantiferon test.
  4. Participants who received vaccinations in the following time frame:

    1. Any within 28 days prior to Screening.
    2. Any subunit vaccine within 14 days prior to Screening.
    3. Any COVID-19 vaccine series within 14 days prior to Screening.
    4. Any other planned vaccine starting 14 days prior to Screening and through study Day 90 and 1 week after. (Note: The annual influenza vaccine is not an exclusion criterion.)
  5. Known or suspected acute infection, including COVID-19 at the time of Screening or within 2 weeks prior to Screening. After confirmed recent COVID-19 infection, a minimum of 2 weeks of recovery post-acute infection is required.
  6. Participants with Screening laboratory test results that are outside the normal limits and considered by the Investigator to be .
  7. Participants with positive test results for surface antigen (HBsAg), virus (HCV) antibody, or (HIV) antigen/antibody as determined at Screening.
  8. Participants with a history of or currently active immune disorders other than T1D (including disease) unless the condition, after discussion with the Medical Monitor, has been deemed to be acceptable for the participant's participation in this study.
  9. Participants with a clinical history of significant cardiovascular disease in the past 12 months.
  10. Participants with a complication or medical history of malignant tumor, other than basal cell or squamous cell carcinomas of the skin.
  11. Participants who, in the Investigator's opinion, will be unable to adhere to study visits and procedures.
  12. Participants who have received therapy other than CNP-103 within 28 days or 5 half-lives, whichever is longer, prior to Screening.
  13. Participants with any known active condition which, in the Investigator's opinion, makes the participant unsuitable for study participation.
  14. Known sensitivity to any components of CNP-103.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Adult Cohort 1 (100 mg CNP-103)

    Three (3) IV administrations of CNP-103 (100 mg) on Days 1, 8, and 90

    Drug: CNP-103 · Drug: Placebo

  • Experimental
    Adult Cohort 2 (300 mg CNP-103)

    Three (3) IV administrations of CNP-103 (300 mg) on Days 1, 8, and 90

    Drug: CNP-103 · Drug: Placebo

  • Experimental
    Adult Cohort 3 (600 mg CNP-103)

    Three (3) IV administrations of CNP-103 (600 mg) on Days 1, 8, and 90

    Drug: CNP-103 · Drug: Placebo

  • Experimental
    Adolescent Cohort 1 (100 mg CNP-103)

    Three (3) IV administrations of CNP-103 (100 mg) on Days 1, 8, and 90

    Drug: CNP-103 · Drug: Placebo

  • Experimental
    Adolescent Cohort 2 (300 mg CNP-103)

    Three (3) IV administrations of CNP-103 (300 mg) on Days 1, 8, and 90

    Drug: CNP-103 · Drug: Placebo

  • Experimental
    Adolescent Cohort 3 (600 mg CNP-103)

    Three (3) IV administrations of CNP-103 (600 mg) on Days 1, 8, and 90

    Drug: CNP-103 · Drug: Placebo

  • Experimental
    Expansion Cohort

    Dosing for the Expansion Cohort will be determined from Escalation Phase results

    Drug: CNP-103 · Drug: Placebo

Interventions

  • DrugCNP-103

    CNP-103

    Also known as: Treatment

  • DrugPlacebo

    0.9% sodium chloride for injection

06

What researchers measure

Primary outcomes

  1. Safety

    Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs), MedDRA 28.1 (CTCAE v. 5.0) or current

    Time frame: Day 1 Through Day 365

  2. Immune Safety

    Serum Cytokines: IL-1β, TNF-α, IL-6, MCP-1, MIP-1α, IFN-γ, IL-4, IL-10

    Time frame: Day 1 Through Day 365

07

Study locations

45 of 45 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Aug 2027, 27 months after the start.

Of 44 phase 1/2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 93. This study's planned 27 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Dec 2026 → Aug 2027 and completion Jun 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2025
First posted
Jan 20, 2025
StartActual
May 12, 2025
Primary completionEst.
Aug 2027was Dec 2026
CompletionEst.
Dec 2027was Jun 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2026→Aug 2027
Nov 12, 2026
Study completion
Jun 2027→Dec 2027
Nov 12, 2026
Contact
Study contact changed: s•••@courpharma.com · •••2551→c•••@courpharma.com · •••0092; removed c•••@courpharma.copm · •••2602. See the current contact
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Dec 2026→Aug 2027
    Study completion Jun 2027→Dec 2027
    Contact Study contact changed: s•••@courpharma.com · •••2551→c•••@courpharma.com · •••0092; removed c•••@courpharma.copm · •••2602. See the current contact

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06783309
Lead sponsor
COUR Pharmaceutical Development Company, Inc.
Responsible party
Sponsor
First posted
Jan 20, 2025
Start date
May 12, 2025
Primary completion
Aug 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

COUR Trial Information
Contact
clinicaltrials@courpharma.com
949-922-0092

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion